Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data

Clearside Biomedical, Inc.

2024-Q2 EPS reported -$0.27 revenue$320,000

Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.
Phase 2b ODYSSEY topline data for wet AMD expected late Q3 2024; no drug-related SAEs observed.
Cash and investments total $29.4M; company expects operations funded into Q3 2025.
Arctic Vision reports positive Phase 3 ARCATUS results; NDAs accepted in Australia and Singapore.
Tony Gibney appointed to Board; Dr. Glenn Yiu added to Scientific Advisory Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.